Ramin Hastings, MD
Interventional Cardiology · Hasbrouck Heights, NJNPI 1477727030
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.9% of it on its own, with 40 other manufacturers making up the rest. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,332 payments — averaging $221.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$197K
- Abbott$29K
- Cardiva Medical, Inc.$25K
- Edwards Lifesciences$19K
- Boston Scientific$13K
- Abiomed$3K
- plus $8K from 35 others
Across 18 payments — averaging $3349.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$50K
- Abbott$10K
What the payments were for
- Consulting fees$42,12514%
- Speaking & faculty fees$176,54860%
- Travel & lodging$25,5749%
- Food & beverage$49,96217%
- Education$2310%
- Entertainment$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 521 | $197,269 |
| Abbott | 104 | $29,127 |
| Cardiva Medical, Inc. | 21 | $24,630 |
| Edwards Lifesciences | 188 | $19,411 |
| Boston Scientific | 143 | $13,078 |
| Abiomed | 98 | $3,111 |
| Biosense Webster, Inc. | 6 | $1,210 |
| W. L. Gore & Associates, Inc. | 12 | $847 |
| Cvrx, Inc. | 9 | $774 |
| Esperion Therapeutics, Inc. | 33 | $581 |
| Cardiovascular Systems Inc. | 9 | $577 |
| Amgen | 36 | $520 |
| Novartis | 31 | $509 |
| Opsens Inc. | 13 | $341 |
| AstraZeneca | 9 | $310 |
| Penumbra, Inc. | 3 | $263 |
| Atricure, Inc. | 7 | $246 |
| Shockwave Medical, Inc | 2 | $206 |
| Philips North America LLC | 9 | $201 |
| Johnson & Johnson | 13 | $191 |
| Teleflex LLC | 2 | $158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $136 |
| Cordis US CORP. | 7 | $117 |
| Angiodynamics, Inc. | 1 | $107 |
| Merck | 6 | $94 |
| Amarin Pharma, Inc. | 7 | $91 |
| Heartflow, Inc. | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 6 | $79 |
| Pfizer | 5 | $74 |
| Boehringer Ingelheim | 4 | $67 |
| Chiesi USA, Inc. | 3 | $40 |
| Cardinal Health 200 LLC | 2 | $38 |
| La Jolla Pharmaceutical Company | 2 | $37 |
| Novo Nordisk | 1 | $32 |
| Acist Medical Systems, Inc. | 1 | $23 |
| Solventum Corporation | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$121,035
- CoreValve Evolut$63,989
- OptoWire$24,106
- MitraClip$7,873
- AMPLATZER AMULET$7,500
- NAVITOR$6,200
- WATCHMAN Access System$5,798
- Edwards SAPIEN 3 Transcatheter Heart Valve$4,841
- MitraClip System$2,625
- AMPLATZER TALISMAN$1,756
- WATCHMAN FLX$1,558
- PASCAL$1,430
- Micra$1,371
- EVOQUE$1,328
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,155
- Thermocool SF$1,088
- Watchman$947
- Impella$657
- AVVIGO Guidance System$560
- Barostim Neo System$531
How this compares
$294,670 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $79,832 |
| Repatha SureclickEvolocumab | 59 | $49,166 |
| XareltoRivaroxaban | 29 | $38,466 |
| Praluent PenAlirocumab | 24 | $34,278 |
| EntrestoSacubitril/Valsartan | 14 | $22,043 |
| JardianceEmpagliflozin | 15 | $17,542 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $14,815 |
| Rosuvastatin Calcium | 133 | $2,464 |
| Metoprolol Succinate | 140 | $1,875 |
| Atorvastatin Calcium | 117 | $1,415 |
| ClopidogrelClopidogrel Bisulfate | 57 | $906 |
| Ranolazine ErRanolazine | 19 | $861 |
| Ezetimibe | 16 | $861 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $792 |
| Losartan Potassium | 65 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $79,83265 claims |
| Johnson & JohnsonXarelto | $191 | $38,46629 claims |
| NovartisEntresto | $509 | $22,04314 claims |
| Boehringer IngelheimJardiance | $67 | $17,54215 claims |
| Esperion Therapeutics, Inc.Nexlizet | $581 | $14,81514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Hasbrouck Heights
- Evan SehgalHasbrouck Heights$60K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.